Skip to main content

Table 1 Baseline characteristics of 55 study patients

From: Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy

Variables % (n) or mean ± SD
Age (yrs) 72 ± 11
Female gender 56.4% (31)
Diabetes mellitus 65.5% (36)
Hypertension 80.0% (44)
Current smoking 34.6% (19)
Dyslipidemia 41.8% (23)
Old stroke 27.3% (15)
Chronic kidney disease (stage I-IV) 27.3% (15)
End-stage renal disease on regular hemodialysis 27.3% (15)
Statin therapy* 50.9% (28)
ACEI/ARB therapy* 58.2% (32)
History of one leg amputation 18.2% (10)
Wound ulceration†  
Grade 0 18.2% (10)
Grade 1 3.6% (2)
Grade 2 5.5% (3)
Grade 3 14.6 (8)
Group 4 60.0% (32)
  1. Data are expressed as mean ± SD or% (n).
  2. *Indicate the drug had already given to the patients ≥ 1 month.
  3. ACEI/ARB = angiotensin converting enzyme inhibitor/angiotensin II receptor type I blocker.